uniQure (QURE)
(Delayed Data from NSDQ)
$4.92 USD
-0.15 (-2.96%)
Updated May 10, 2024 04:00 PM ET
After-Market: $4.93 +0.01 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QURE 4.92 -0.15(-2.96%)
Will QURE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QURE
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
Other News for QURE
Buy Rating Affirmed for uniQure Amid Strong Pipeline and Regulatory Progress
Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Siemens Healthineers AG (OtherSEMHF) and uniQure (QURE)
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and uniQure (QURE)
Stifel Nicolaus Sticks to Its Buy Rating for uniQure (QURE)
uniQure price target lowered by $3 at Leerink, here's why